Skip to main content
Clinical Trials/NCT06217562
NCT06217562
Active, not recruiting
Phase 4

Vasopressin for Septic Shock Pragmatic Trial

Intermountain Health Care, Inc.13 sites in 1 country2,050 target enrollmentFebruary 1, 2024

Overview

Phase
Phase 4
Intervention
Vasopressin
Conditions
Septic Shock
Sponsor
Intermountain Health Care, Inc.
Enrollment
2050
Locations
13
Primary Endpoint
28-day all-cause mortality
Status
Active, not recruiting
Last Updated
6 months ago

Overview

Brief Summary

Life-threatening low blood pressure due to a serious infection is called "septic shock." Septic shock is treated with vasopressors, medications that raise blood pressure. Sometimes first-line vasopressors are inadequate, prompting addition of a second-line vasopressor called vasopressin. However, the threshold at which to start vasopressin remains unclear. This pragmatic, cluster-randomized, cluster-crossover trial will evaluate two different strategies for septic shock treatment commonly used in current practice, comparing a lower versus a higher threshold for adding vasopressin to first-line vasopressors.

Registry
clinicaltrials.gov
Start Date
February 1, 2024
End Date
December 1, 2027
Last Updated
6 months ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age ≥18 years
  • Admitted to a study hospital emergency department (ED) or inpatient care unit
  • Administration of vasopressor(s) for septic shock

Exclusion Criteria

  • Not provided

Arms & Interventions

Septic shock treatment strategy involving a lower threshold for vasopressin initiation

Recommended strategy for treatment of septic shock includes initiation of fixed-dose IV vasopressin (1.8 units/hour) as a second-line vasopressor if the combined norepinephrine-equivalent dose of other vasopressors reaches ≥0.1 micrograms/kilogram/minute (mcg/kg/min). Use of the recommended treatment strategy (via entry of an order for threshold-based vasopressin initiation) or an alternative treatment strategy is at the discretion of patients' treating clinical team.

Intervention: Vasopressin

Septic shock treatment strategy involving a lower threshold for vasopressin initiation

Recommended strategy for treatment of septic shock includes initiation of fixed-dose IV vasopressin (1.8 units/hour) as a second-line vasopressor if the combined norepinephrine-equivalent dose of other vasopressors reaches ≥0.1 micrograms/kilogram/minute (mcg/kg/min). Use of the recommended treatment strategy (via entry of an order for threshold-based vasopressin initiation) or an alternative treatment strategy is at the discretion of patients' treating clinical team.

Intervention: Recommendation to use a lower initiation threshold for vasopressin

Septic shock treatment strategy involving a higher threshold for vasopressin initiation

Recommended strategy for treatment of septic shock includes initiation of fixed-dose IV vasopressin (1.8 units/hour) as a second-line vasopressor if the combined norepinephrine-equivalent dose of other vasopressors reaches ≥0.4 mcg/kg/min. Use of the recommended treatment strategy (via entry of an order for threshold-based vasopressin initiation) or an alternative treatment strategy is at the discretion of patients' treating clinical team.

Intervention: Vasopressin

Septic shock treatment strategy involving a higher threshold for vasopressin initiation

Recommended strategy for treatment of septic shock includes initiation of fixed-dose IV vasopressin (1.8 units/hour) as a second-line vasopressor if the combined norepinephrine-equivalent dose of other vasopressors reaches ≥0.4 mcg/kg/min. Use of the recommended treatment strategy (via entry of an order for threshold-based vasopressin initiation) or an alternative treatment strategy is at the discretion of patients' treating clinical team.

Intervention: Recommendation to use a higher initiation threshold for vasopressin

Outcomes

Primary Outcomes

28-day all-cause mortality

Time Frame: 28 days

Death on or before study day 28

Secondary Outcomes

  • Renal replacement therapy-free days to day 28(28 days)

Study Sites (13)

Loading locations...

Similar Trials